person · Reporting owner
WRIGHT TIMOTHY MICHAEL
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Regulus Therapeutics Inc.RGLS · Entity 78034 | Chief R & D Officer | February 05, 2019 | February 06, 2019 |
| Schrodinger, Inc.SDGR · Entity 4667 | Director | February 10, 2020 | February 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Regulus Therapeutics Inc.
Report date February 05, 2019 · Filed February 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,893 |
Reported balance
After 2019-02-05 transaction · row 1
1 source rowRow 1 · 2019-02-05 · Grant · Acquired 40,000 · Balance 62,893 F1: Restricted Stock Units which vest ratably on a quarterly basis such that the grant is fully vested on December 31, 2019, subject to the reporting person's continuous service to Regulus through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2029-02-04 | Direct | 40,000 |
Reported balance
After 2019-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-05 · Grant · Acquired 40,000 · Balance 40,000 F2: The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units which vest ratably on a quarterly basis such that the grant is fully vested on December 31, 2019, subject to the reporting person's continuous service to Regulus through each such vesting date.
F2: The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.
Schrodinger, Inc.
Report date February 10, 2020 · Filed February 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2030-02-04 | Direct | 12,909 |
Reported balance
After 2020-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-10 · Grant · Acquired 12,909 · Balance 12,909 F1: The option was granted on February 5, 2020. The commencement of vesting was contingent upon the closing of the Issuer's initial public offering, which occurred on February 10, 2020. The shares underlying the option are scheduled to vest in full on February 5, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on February 5, 2020. The commencement of vesting was contingent upon the closing of the Issuer's initial public offering, which occurred on February 10, 2020. The shares underlying the option are scheduled to vest in full on February 5, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2020 Filed Feb 10, 2020 16:09 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 12,909 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003801 · doc4.xml · derivative · entry 1 WRIGHT TIMOTHY MICHAEL · CIK 0001686178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,909 Underlying: Common Stock · 12,909 shares Expires 2030-02-04 F1 · derivative.exercise_date: The option was granted on February 5, 2020. The commencement of vesting was contingent upon the closing of the Issuer's initial public offering, which occurred on February 10, 2020. The shares underlying the option are scheduled to vest in full on February 5, 2021. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 16:52 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001209191-19-007778 · doc4.xml · derivative · entry 2 WRIGHT TIMOTHY MICHAEL · CIK 0001686178 · Chief R & D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-04 F2 · derivative.exercise_date: The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 16:52 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | GrantCommon Stock | 40,000 | $0.95 | $38,000.00 |
DisclosureSEC source: 0001209191-19-007778 · doc4.xml · nonDerivative · entry 1 WRIGHT TIMOTHY MICHAEL · CIK 0001686178 · Chief R & D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,893 F1 · shares: Restricted Stock Units which vest ratably on a quarterly basis such that the grant is fully vested on December 31, 2019, subject to the reporting person's continuous service to Regulus through each such vesting date. Read SEC document |
| May 17, 2018 Filed May 21, 2018 16:45 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-18-031900 · doc4.xml · derivative · entry 1 WRIGHT TIMOTHY MICHAEL · CIK 0001686178 · Chief R & D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: The option will vest in forty-eight equal monthly installments, such that the option will be fully vested four years from the date of grant, subject to the Reporting Person's continuous service to us. Read SEC document |
| January 05, 2018 Filed Jan 5, 2018 18:58 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-18-002556 · doc4.xml · derivative · entry 1 WRIGHT TIMOTHY MICHAEL · CIK 0001686178 · Chief R & D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-01-04 F1 · derivative.exercise_date: The option will vest in forty-eight equal monthly installments, such that the option will be fully vested four years from the date of grant, subject to the Reporting Person's continuous service to us. Read SEC document |
| December 04, 2017 Filed Dec 5, 2017 09:31 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-063711 · doc4.xml · derivative · entry 1 WRIGHT TIMOTHY MICHAEL · CIK 0001686178 · Chief R & D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-10-02 F1 · balance_after: On October 3, 2016, the reporting person was granted an option to purchase 400,000 shares of common stock. The option vests in increments of 100,000 shares upon the achievement of certain performance criteria. On December 4, 2017, the performance criteria for the first goal were met, resulting in the vesting of 100,000 shares. Read SEC document |
| July 25, 2017 Filed Jul 25, 2017 18:09 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | PurchaseCommon Stock | 274,725 | $0.91 | $249,999.75 |
DisclosureSEC source: 0001209191-17-046235 · doc4.xml · nonDerivative · entry 1 WRIGHT TIMOTHY MICHAEL · CIK 0001686178 · Chief R & D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,725 Read SEC document |
| May 04, 2017 Filed May 8, 2017 16:25 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001209191-17-030593 · doc4.xml · derivative · entry 1 WRIGHT TIMOTHY MICHAEL · CIK 0001686178 · Chief R & D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2027-05-03 F1 · derivative.exercise_date: 25% of the shares vest on May 4, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on May 4, 2021. Read SEC document |
| February 15, 2017 Filed Feb 23, 2017 17:23 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | GrantStock Option (Right to Buy) · Derivative | 32,412 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-17-013906 · doc4.xml · derivative · entry 1 WRIGHT TIMOTHY MICHAEL · CIK 0001686178 · Chief R & D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,412 Underlying: Common Stock · 32,412 shares Expires 2027-02-14 F1 · derivative.exercise_date: 25% of the shares vest on January 1, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on January 1, 2021. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 16:59 UTC | Regulus Therapeutics Inc. RGLS · Entity 78034 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-16-145038 · doc4.xml · derivative · entry 1 WRIGHT TIMOTHY MICHAEL · CIK 0001686178 · Chief R & D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2026-10-02 F1 · derivative.exercise_date: 25% of the shares vest on October 3, 2017 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on October 2, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.